ePrints

Resistance acquisition to MDM2 inhibitors

Lookup NU author(s): Dr Ian HardcastleORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Various experimental strategies aim to (re)activate p53 signalling in cancer cells. The most advanced clinically are small-molecule inhibitors of the autoregulatory interaction between p53 and MDM2 (murine double minute 2). Different MDM2 inhibitors are currently under investigation in clinical trials. As for other targeted anti-cancer therapy approaches, relatively rapid resistance acquisition may limit the clinical efficacy of MDM2 inhibitors. In particular, MDM2 inhibitors were shown to induce p53 mutations in experimental systems. In the present article, we summarize what is known about MDM2 inhibitors as anti-cancer drugs with a focus on the acquisition of resistance to these compounds.

Publication metadata

Author(s): Cinatl J, Speidel D, Hardcastle I, Michelis M

Publication type: Review

Publication status: Published

Journal: Biochemical Society Transactions

Year: 2014

Volume: 42

Issue: 4

Pages: 752–757

Print publication date: 01/08/2014

ISSN (print): 0300-5127

ISSN (electronic): 1470-8752

URL: http://www.biochemsoctrans.org/content/ppbiost/42/4/752.full.pdf

DOI: 10.1042/BST20140035

Share